GlassScriptPhysician profile
Vineshkumar Patel
NPI 1730112632
$7,861.37
in general payments reported to CMS, 2019-2025
31 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $175 · 2021: $1,178 · 2022: $1,631 · 2023: $1,637 · 2024: $1,527 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,096.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,669.26 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $911.93 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $858.94 | 2019-2025 | |
| Pfizer INC. | $640.86 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $609.74 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $574.29 | 2019-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $502.61 | 2019-2025 | Bodyguardian |
| Impulse Dynamics (USA) INC. | $394.08 | 2022-2025 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.08 | 2022-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $276.49 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $197.06 | 2023-2025 | |
| Abbott Laboratories | $155.71 | 2022-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Bridgebio Pharma, INC. | $151.96 | 2025 | Attruby |
| Amgen INC. | $116.96 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $93.37 | 2019-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $58.83 | 2020-2023 | Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $42.23 | 2023 | Inpefa |
| Preventice Services, LLC | $39.83 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $35.68 | 2024 | Arcalyst |
| Philips North America LLC | $32.64 | 2023-2024 | (5044) Mcot |
| Novo Nordisk INC | $32.53 | 2021-2025 | Ozempic |
| Daiichi Sankyo INC. | $31.23 | 2022-2023 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $30.25 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $24.13 | 2021 | |
| Acera Surgical, INC. | $21.62 | 2025 | Restrata Wound Matrix |
| Bayer Healthcare Pharmaceuticals INC. | $19.84 | 2024 | |
| Genentech USA, INC. | $18.05 | 2025 | Xolair |
| Harmony Biosciences LLC | $14.06 | 2023 | Wakix |
| Regeneron Healthcare Solutions, INC. | $13.72 | 2019 | |
| Csl Behring | $11.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineshkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.